Peripheral vascular disease articles

EuroPCR 2023 | New Renal Denervation Devices Show Promising Results

EuroPCR 2023 | New Renal Denervation Devices Show Promising Results

The Netrod System study included 205 patients with uncontrolled essential hypertension while taking two drugs (nifedipine and hydrochlorothiazide), who were randomized 2:1 to denervation or sham control. All subjects had undergone renal angiography before randomization. Renal denervation was done using the Setrod System device. Mean patient age was 50 years old, and 16% of subjects were female.

EuroPCR 2023 | More Evidence in Favor of Renal Denervation

This study included 219 patients with uncontrolled essential hypertension who had received at least two antihypertensive drugs. All of them underwent a renal angiography and were randomized to the renal denervation group or the control group. Denervation was performed using the SyMapCath I catheter and the SYMPIONEER S1 generator/stimulator. Mean patient age was 45 years old, and

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

Drug Coated Balloons: Link between Femoropopliteal Lesion Calcification Grade and Clinical Outcomes

At present, the use of drug coated balloons (DCB) in femoropopliteal territory is more and more frequent. However, when it comes to treating moderate to severe calcification, the evidence is still limited.   Using a peripheral artery calcification scoring system (PACSS) has been associated to clinical outcomes after DCB angioplasty for femoropopliteal lesions. The system categorizes

Un guiño para la trombólisis guiada por Catéter en tromboembolismo pulmonar

CLOUT Registry: Thrombectomy in TVP with ClotTriever

Safety and efficacy of the ClotTriever device in extended deep vein thrombosis.  The endovascular treatment of thromboembolic disease has evolved and new devices have come out in the last few years to reduce morbimortality from its complications. Sub-treating this pathology has long term implications, such as reduced quality of life, limiting functional class and, worst

Acceso retrógrado mediante la arteria tibial para el tratamiento de oclusiones en territorio femoropoplíteo: ¿es una estrategia segura?

Retrograde Tibial Access for Endovascular Treatment of Femoropopliteal Occlusions: Is it a Safe Strategy?

Endovascular recanalization of femoropopliteal occlusions continues to be one of the initial therapeutic strategies to treat this pathology.  The anterograde approach via the common femoral is the most frequently used. However, it is not always viable, especially in long occlusions with severe calcification or when the femoral artery cannot be reached. In these cases, the

Isquemia crítica de miembros inferiores: el blush de la herida

Deep Vein Arterialization: Have We Conquered “Non-Revascularizable” Critical Limb Ischemia?

Deep vein Arterialization in patients with critical “non-revascularizable” limb ischemia.  We are familiar with the poor quality of life and elevated mortality of patients with chronic limb-threatening ischemia (CLTI). In its last stages (nearly terminal), revascularization (either surgical or endovascular) has been shown to reduce amputation incidence.  However, similarly to heart disease and other vascular scenarios,

SAFE-AAA: ¿Son seguros los dispositivos Endologix en aneurisma de aorta abdominal? Seguimiento a 3 años

SAFE-AAA: Are the New Endologix Devices for Abdominal Aortic Aneurysm Safe? 3-Year Followup

New unibody endologix endografts for the endovascular repair of abdominal aortic aneurysm 3-4-year safety followup  At present, we have seen endovascular intervention of abdominal aortic aneurysm (EVAR) increase over surgical repair. However, the procedure is not free from complications, endoleak being the most frequent. Indeed, according to different series, it has a 20-25% incidence in AAA.  Most

Desafíos pendientes con el acceso radial

TAVR: Vascular Access in Patients with Peripheral Artery Disease, 1-Year Outcomes

At present, the transfemoral access (TFA) is the preferred approach when it comes to transcatheter aortic valve replacement (TAVR). However, 5 to10% of PAD patients present tortuous iliac anatomy and calcification, aortic aneurysms or prior peripheral intervention, which makes it impossible.  There are several alternatives to approach these patients: 1) TFA associated to peripheral PCI

Subutilización del tratamiento médico en enfermedad vascular periférica

Relationship Between Medical Treatment and Long-Term Clinical Results after Peripheral Vascular Intervention

Peripheral arterial disease (PAD) is one of the consequences of atherosclerosis, and it can cause pain in the limbs or tissue loss. Its treatment includes lifestyle changes such as exercise, statin therapy, antiplatelet therapy, antihypertensive medication (mainly ACE inhibitors or ARBs), and revascularization strategy. One in five patients with PAD will have experienced acute myocardial

Reestenosis de bordes con stents liberadores de everolimus

Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons

Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the rate of restenosis in obstructive femoropopliteal lesions compared with conventional balloons or conventional stents (bare-nitinol stent, BNS). Both in the placement of BNS and of drug-eluting stents (DES) there is a mechanical risk of stent fracture or